Cancer is the abnormal growth of cells that tend to proliferate in an uncontrolled way. About 32.6 million people in the world are affected by different types of cancer; 456 000 have esophageal cancer, which is the eighth most common cancer and the sixth most common cause of cancer-related deaths with a toll of 400 000 in 2012. About 80% of cases were reported from the less developed regions of the world. An incidence ratio of 2.4 : 1 for men and women reveals the gender disparity. Esophageal cancer is mainly of two types, namely, squamous cell carcinoma and adenocarcinoma. Most of the studies show a positive correlation of esophageal cancer with alcohol and tobacco consumption, but a negative correlation with fruit and vegetable intake. The type and amount of cereal, fat, meat and beverages consumed are also under study. Significant statistical synergistic interaction has been registered in studies considering the joint effect of the amount of beverage swallowed and its temperature, especially among heavy consumers. The role of non-nutritional components is gaining increasing attention because of their antioxidant, anti-inflammatory, anti-mutagenic and anti-carcinogenic properties. Socioeconomic status is another factor that cannot be ignored. Nevertheless, the predominant cause appears to be different in different regions, and in spite of the great advancements in the medical field, this still remains an enigma for researchers.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1039/c7fo01908d | DOI Listing |
J Biochem Mol Toxicol
February 2025
Department of Obstetrics and Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
This study aims to investigate the expression of GPER in EC, assess the impact of estrogen on the proliferation and migration of EC via GPER, and examine the potential role of GPER in mediating the NOTCH pathway to influence EC proliferation and migration. The expression of GPER and its correlation with clinicopathological features were investigated using clinical data. Cell proliferation was assessed through MTT and EdU assays, while cell migration ability was evaluated using wound healing and transwell assays.
View Article and Find Full Text PDFInt J Surg
January 2025
Department of Radiotherapy, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Cancer Hospital of Dalian University of Technology, Shenyang, China.
J Med Chem
January 2025
College of Chemistry, Zhengzhou University, Zhengzhou 450001, China.
The P2YR is activated by UDP and UDP glucose and is involved in many human inflammatory diseases. Based on the molecular docking analysis of currently reported P2YR antagonists and the crystallographic overlap study between PPTN and compound , a series of 3-substituted 5-amidobenzoate derivatives were designed, synthesized, and identified as promising P2YR antagonists. The optimal compound (methyl 3-(1-benzo[]imidazol-2-yl)-5-(2-(-tolyl) acetamido)benzoate, IC = 0.
View Article and Find Full Text PDFWorld J Gastroenterol
January 2025
Department of Thoracic Surgery, Northern Jiangsu People's Hospital, Yangzhou 225000, Jiangsu Province, China.
Background: The relationship between patient nutritional, immune, and inflammatory status is linked to tumor progression and prognosis. However, there are limited studies on the prognosis of esophageal squamous cell carcinoma (ESCC) after surgery based on the comprehensive indicators of these factors.
Aim: To develop and validate a novel nomogram based on a nutritional immune-inflammatory status (NIIS) score for predicting postoperative outcomes in ESCC.
Oncol Lett
March 2025
Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Kyoto 602-8566, Japan.
Nivolumab has been approved for unresectable recurrent advanced esophageal cancer. The present study aimed to provide real-world data on diverse patient profiles, including the elderly and those with poor performance status, while exploring therapeutic efficacy biomarkers. This retrospective study included 42 patients with esophageal cancer who received nivolumab after second- or later-line treatment at Kyoto Prefectural University of Medicine (Kyoto, Japan) from February 2020 to December 2021.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!